<DOC>
	<DOCNO>NCT00482716</DOCNO>
	<brief_summary>RATIONALE : Epoetin alfa epoetin beta may cause body make red blood cell . Red blood cell contain iron need carry oxygen tissue . It yet know whether epoetin alfa epoetin beta effective give without iron infusion treat anemia patient cancer . PURPOSE : This randomized phase III trial study epoetin alfa epoetin beta compare well work without iron infusion treat anemia patient cancer .</brief_summary>
	<brief_title>Epoetin Alfa Epoetin Beta With Without Iron Infusion Treating Anemia Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy recombinant epoetin alfa epoetin beta v without parenteral iron anemic , iron-replete patient nonmyeloid malignancy . OUTLINE : This randomize , control , open-label , prospective study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive recombinant erythropoietic stimulatory activity ( ESA ) therapy comprise epoetin alfa epoetin beta subcutaneously ( SC ) day 1 . - Arm II : Patients receive ESA therapy arm I parenteral iron ( i.e. , low molecular weight iron dextran complex IV 5-10 minute iron sucrose injection IV 10-30 minute ) day 1 . In arm , treatment repeat weekly 10 week hemoglobin reach 13 g/dL , whichever come first .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonmyeloid malignancy No primary bone marrow malignancy except multiple myeloma , chronic lymphocytic leukemia , indolent nonHodgkin lymphoma Candidate erythropoietin stimulatory activity therapy anemia due cancer and/or chemotherapy Baseline hemoglobin ≤ 10.5 g/dL Planning receive ≥ 6 additional week chemotherapy malignancy Demonstrates ironreplete status define follow parameter : Percent saturation transferrin ≥ 20 % Serum ferritin 2252,250 pmol/L Reticulocyte hemoglobin content &gt; 31 pg Zinc protoporphyrin &lt; 80 µg/dL No anemia origin cancer cancer chemotherapy PATIENT CHARACTERISTICS : ECOG performance status 02 No allergy intolerance recombinant epoetin alfa epoetin beta No known sensitivity iron sucrose injection iron dextran complex No uncontrolled hypertension No active infection No active bleeding PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior iron sucrose injection iron dextran complex therapy More 6 month since prior concurrent transfusion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>anemia</keyword>
</DOC>